Investors and Media

Press Releases

August 15, 2025

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 14, 2025

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

August 6, 2025

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

July 21, 2025

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

July 18, 2025

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 23, 2025

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

June 18, 2025

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

June 13, 2025

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Archived Press Releases